Enlightening light chain deposition disease

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

In this issue of Blood, Sayed et al report on a series of 53 patients with light chain (LC) deposition disease (LCDD) prospectively followed for a median of 6.2 years, showing divergent outcomes in patients who achieve a very good partial response (VGPR) or complete response (CR) compared with those who do not (see figure, panel A). Even patients with advanced chronic kidney disease (CKD) benefited from a deep clonal response.

Original languageEnglish
Pages (from-to)2770-2771
Number of pages2
JournalBlood
Volume126
Issue number26
DOIs
Publication statusPublished - Dec 24 2015

Fingerprint

Light
Blood
Chronic Renal Insufficiency

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Enlightening light chain deposition disease. / Merlini, Giampaolo; Palladini, Giovanni.

In: Blood, Vol. 126, No. 26, 24.12.2015, p. 2770-2771.

Research output: Contribution to journalArticle

@article{9de989d8604b43bea9176aeba9eaa303,
title = "Enlightening light chain deposition disease",
abstract = "In this issue of Blood, Sayed et al report on a series of 53 patients with light chain (LC) deposition disease (LCDD) prospectively followed for a median of 6.2 years, showing divergent outcomes in patients who achieve a very good partial response (VGPR) or complete response (CR) compared with those who do not (see figure, panel A). Even patients with advanced chronic kidney disease (CKD) benefited from a deep clonal response.",
author = "Giampaolo Merlini and Giovanni Palladini",
year = "2015",
month = "12",
day = "24",
doi = "10.1182/blood-2015-10-672626",
language = "English",
volume = "126",
pages = "2770--2771",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "26",

}

TY - JOUR

T1 - Enlightening light chain deposition disease

AU - Merlini, Giampaolo

AU - Palladini, Giovanni

PY - 2015/12/24

Y1 - 2015/12/24

N2 - In this issue of Blood, Sayed et al report on a series of 53 patients with light chain (LC) deposition disease (LCDD) prospectively followed for a median of 6.2 years, showing divergent outcomes in patients who achieve a very good partial response (VGPR) or complete response (CR) compared with those who do not (see figure, panel A). Even patients with advanced chronic kidney disease (CKD) benefited from a deep clonal response.

AB - In this issue of Blood, Sayed et al report on a series of 53 patients with light chain (LC) deposition disease (LCDD) prospectively followed for a median of 6.2 years, showing divergent outcomes in patients who achieve a very good partial response (VGPR) or complete response (CR) compared with those who do not (see figure, panel A). Even patients with advanced chronic kidney disease (CKD) benefited from a deep clonal response.

UR - http://www.scopus.com/inward/record.url?scp=84954489896&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954489896&partnerID=8YFLogxK

U2 - 10.1182/blood-2015-10-672626

DO - 10.1182/blood-2015-10-672626

M3 - Article

VL - 126

SP - 2770

EP - 2771

JO - Blood

JF - Blood

SN - 0006-4971

IS - 26

ER -